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Abstract
In July 2010, the World Health Organization (WHO) issued formal revisions of its guidelines on the use of highly
active antiretroviral therapy for HIV. The new guidelines greatly expand eligibility for treatment of adults and
children, as well as for pregnant women seeking prophylaxis for vertical HIV transmission. WHO’s new
recommendations bring the guidelines closer to practices in developed countries, and its shift to earlier treatment
alone will increase the number of treatment-eligible people by 50% or more.
Scaling up access to HIV treatment is revealing important gaps in our understanding of how best to provide for all
those in need. This knowledge gap is especially significant in developing countries, where women and children
comprise a majority of those living with HIV infection. Given the magnitude and significance of these populations,
the International AIDS Society, through its Industry Liaison Forum, prioritized HIV treatment and prophylaxis of
women and children. In March 2010, the International AIDS Society and 15 partners launched a Consensus
Statement outlining priority areas in which a relative lack of knowledge impedes delivery of optimal prevention of
mother to child transmission (PMTCT) and treatment to women and children.
The Consensus Statement, “Asking the Right Questions: Advancing an HIV Research Agenda for Women and
Children”, makes a special appeal for a more gender-sensitive approach to HIV research at all stages, from
conception to design and implementation. It particularly emphasizes research to enhance the understanding of
sex-based differences and paediatric needs in treatment uptake and response. In addition to clinical issues, the
statement focuses on programmatic research that facilitates access and adherence to antiretroviral regimens. Better
coordination of HIV management with sexual and reproductive healthcare delivery is one such approach.
We discuss here our knowledge gaps concerning effective, safe PMTCT and treatment for women and children in
light of the expansion envisioned by WHO’s revised guidelines. The guideline’s new goals present an opportunity
for advancing the women and children’s agenda outlined in the Consensus Statement.
Commentary
In July 2010, the World Health Organization (WHO)
issued formal revisions of its guidelines on the use of
highly active antiretroviral therapy for HIV. The guide-
lines greatly expand eligibility for treatment of adults [1]
and children [2]. They also broaden the armamentarium
for prevention of mother to child transmission
(PMTCT) of HIV [3]. WHO’s recommendations, which
apply mainly to resource-restricted settings, bring the
guidelines closer to the practices in developed countries
[4]. At the same time, they will increase the number of
treatment-eligible patients by 50% or more [5].
Changes in HIV treatment access are of special con-
cern to women and children. Women notably constitute
60% of the people living with HIV in the high-burden
countries of sub-Saharan Africa [6]. Furthermore, expec-
tant HIV-infected mothers face the combined hazard of
virus- and pregnancy-related health issues; they have
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higher than their HIV-uninfected peers [7]. This excess
mortality might seem self-evident, yet research has yet
to break down the various contributing factors, includ-
ing AIDS or other comorbidities and obstetric condi-
tions aggravated by immune deficiency. Children in the
least developed countries, meanwhile, suffer from the
maternal HIV epidemic, as well as the paediatric one,
leading to enhancement of a third concurrent epidemic,
malnutrition.
Considering the need to optimize the benefits of anti-
retroviral treatment for women and children, the Inter-
national AIDS Society’s Industry Liaison Forum (IAS-
ILF) launched a mapping exercise to examine the need
for further clinical and operations research related to
HIV treatment and PMTCT [8]. The mapping exercise
resulted in the Consensus Statement, “Asking the Right
Questions: Advancing an HIV Research Agenda for
Women and Children”, which was released on 8 March
2010 by the IAS and 15 partners, including United
Nations agencies, community groups, the private sector
and foundations [9]. The statement develops a useful
roadmap for developing the means to expand optimum
HIV care for women and children in the manner envi-
sioned by WHO’s 2010 HIV guidelines. We discuss here
in detail the missing pieces in our knowledge of optimal
HIV treatment in women and children and advocate
advancing this research agenda.
Overcoming the hurdles to treating HIV in women
The WHO guidelines advance the CD4 count threshold
for initiating treatment in patients older than five years
to 350 cells/mm
3 from the previous limit of 200 cells/
mm
3 [1]. All patients with clinically advanced HIV
(WHO stages 3 and 4) are also eligible.
These criteria hold for women, as well as for men. Yet
an old but unresolved debate is whether there are biolo-
gical differences between men and women that influence
disease progression and treatment outcome. Two stu-
dies, each enrolling more than 2000 participants, have
reported that women on antiretroviral (ARV) drugs have
higher CD4 counts and slower disease progression than
men [10,11]. Other studies have not observed any differ-
ences [12,13]. Resolution of this issue is made difficult
by short follow up and many confounding factors, such
as concurrent health problems, care access, ethnic origin
and socioeconomic factors.
Another area of uncertainty over sex differences con-
cerns pharmacokinetics and toxicities. These issues arise
for nevirapine and efavirenz, the two drugs that provide
the high potency of WHO’s preferred first-line combina-
tion regimens. There are long-established sex differences
in nevirapine’s adverse effects: women with higher CD4
counts are more at risk than men at the same CD4
count for hypersensitivity reactions and hepatic failure
after starting the drug [14,15]. Recent studies have con-
tested this CD4 association, however [16,17]. An analysis
of efavirenz found equal virologic and immunologic
improvements in men and women, but more frequent
toxicity-related drug discontinuations in women [18]. In
treatment outcome studies, factors such as race, lower
body weight or liver function differences may confound
the results.
A third major area in which sex can complicate treat-
ment decisions is hormonal contraceptives. Although
there is as yet no evidence that hormonal contraception
interferes with ARVs, there is evidence that the reverse
is true. Women receiving nevirapine- or ritonavir-con-
taining regimens (which are favoured by WHO for sec-
ond-line therapy) will more rapidly metabolize ethinyl
oestradiol and norethindrone taken for contraceptive
purposes. Progesterone-based contraceptives may still be
feasible, however [19].
There are also controversies over the effect of hormo-
nal contraception on HIV progression. Some published
data suggest that hormonal contraception increases the
risk of HIV acquisition [20] or disease progression [21],
whereas other studies contradict these results [22,23].
There is an urgent need to conclusively resolve this
question.
In addition, there has been little investigation of the
interaction between ARVs and the female hormone
changes that women experience in the course of their
lives. A number of studies have found that pregnancy
reduces antiretroviral drug levels [24]. There are also
indications that some women on ARVs undergo earlier
onset of menopause [25].
In contrast, the relationship between ARVs and pub-
erty is uncharted territory. It is possible, for example,
that ARVs contribute to delaying puberty even though
they reverse the endocrine-disrupting effects of chronic
HIV [26]. Once teenagers do achieve puberty, optimal
HIV treatment may be difficult to achieve because pub-
escent adolescents have unexpectedly low drug levels
despite reasonable adherence [27] and are at increased
risk of ARV-associated metabolic dysfunction [28]. With
the growing availability of paediatric antiretroviral treat-
ment, an increasing number of children are surviving
into and through adolescence. The long overlooked
research on this age group’sr e s p o n s et oA R V sh a s
become a pressing issue.
Women are in a more vulnerable position than men
in many parts of the world, and often their lesser socio-
economic status and decision-making power constrains
their ability to seek out care on their own [29-31].
Nonetheless, a greater proportion of women than men
with HIV are diagnosed and receive ARVs. Due to their
biologic, social and family roles, women more readily
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receive HIV testing [32-34] and care [34-36].
Women would benefit, therefore, from an integration
of HIV programmes with broader sexual and reproduc-
tive health services [37,38]. This possibility signals the
need to intensify oft-ignored operations research into
women’s care delivery. Such research, which includes
programme evaluations, can show how to optimize anti-
retroviral therapy by improving HIV diagnosis and long-
term follow up of women at different socioeconomic
levels. The need is particularly critical for marginalized
subpopulations of adolescent and adult women. Women
living in remote areas, single women, widows, sex work-
ers, women who use drugs, transgender individuals and
women who are indigent or from racial minorities
should receive special attention.
Extending prophylaxis for prevention of vertical
transmission
In 2008, an estimated 45% of pregnant women in
resource-limited countries received PMTCT regimens,
but these were generally simpler and shorter than the
regimens that WHO now advocates [39].
The 2010 PMTCT guidelines primarily advise provi-
sion of potent triple antiretroviral therapy for prevention
of vertical transmission in pregnant women [3]. Thus,
pregnant women who present at prenatal clinics with
serious HIV-related symptoms or CD4 counts below
350 cells/mm
3 will receive a highly suppressive antire-
troviral regimen, as recommended for all adults for their
own health. The triple regimen will also minimize the
risk of transmission of HIV to the foetus and breastfeed-
ing infant.
The new WHO guidelines propose that expectant
HIV-positive mothers with CD4 counts above 350 cells/
mm
3 receive triple-drug regimens, too, starting at 14
weeks of gestation and continuing through weaning [3].
Evidence shows that suppressive combination therapy
from late pregnancy through six months of breastfeed-
ing can reduce mother to child HIV transmission to
below 1% [40].
The guidelines, in addition, offer a cheaper option for
women with CD4 counts above the 350 cells/mm
3
threshold: of zidovudine monotherapy from 14 weeks of
gestation until birth. Mothers may also receive single-
dose nevirapine during labour, plus a week of zidovu-
dine/lamivudine combination post-partum. Breastfeeding
infants in this case receive nevirapine prophylaxis until
weaned. Non-breastfeeding infants receive nevirapine or
zidovudine for six weeks after birth.
Studies that examine and compare the efficacy of
WHO’s two PMTCT options, triple regimen versus sim-
plified regimen, would be very valuable. An 805-birth
study in three African countries found no significant
difference in pre-birth transmission rates when compar-
ing three-drug regimens to what is now the simpler
WHO alternative (though starting only after week 26)
[41]. As for transmission during breastfeeding, a trial
following 2369 Malawi births reported no significant dif-
ference between maternal triple therapy and infant daily
nevirapine [42].
Another outstanding question is the impact of inter-
mittent therapy on women’s future treatment options.
There is growing evidence that administering single-
dose nevirapine during labour - the most common
PMTCT regimen used in low-income countries -
increases the risk of developing nevirapine-resistant HIV
[43]. The revised guidelines recommend seven days of
zidovudine/lamivudine post-partum to overcome this
problem by inhibiting HIV replication while the nevira-
pine is slowly being cleared from the mother’s body.
Additional studies are needed to address resistance con-
cerns of the guideline revisions, in particular, conse-
quences of zidovudine monotherapy from 14 weeks of
gestation and continued during pregnancy [44].
Furthermore, the Strategies for Management of Anti-
retroviral Therapy (SMART) trial found that episodic
HIV-suppressive ARV combinations result in greater
mortality and morbidity than continuous therapy
[45,46]. Initial research has not confirmed this increase
in women who terminate ARVs after delivery, but defi-
nitive data for women with CD4 counts of more than
350 cells/mm
3 are not yet available [47].
WHO’s PMTCT revisions raise a number of opera-
tional issues concerning the ability of treatment pro-
grammes to accommodate the new recommendations.
Initial studies indicate that instituting the new recom-
mendations would triple the number of HIV infections
averted [48,49]. Having effective regimens is not enough
all by itself, however; effective delivery programmes are
even more important [50].
There remain many research questions involving
delivery of extended PMTCT [9]. Central to this effort
is, once again, integration of services [51,52]: healthcare
systems need to investigate the feasibility of providing
antiretrovirals to pregnant women as part of routine
maternal care in antenatal clinics. Task shifting and task
sharing, which allow lower-level healthcare staff to
assume greater responsibilities, could be of great assis-
tance here [53]. Retention strategies are critical, too.
Investigating the best means for maintaining contact
with HIV-positive mothers and their infants is vital for
PMTCT success. Family-centered care, which meets the
continuing health needs of the entire household, may be
a key strategy here [54]. Local programmes will have to
learn how to adapt to their clients’ cultural background,
providing services that make them feel respected and
safe.
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Under the 2010 WHO guidelines, infants could have up
to more than two years of in utero and post-partum
antiretroviral drug exposure [3]. The immediate prophy-
lactic benefits of this extended exposure are well recog-
nized and outweigh any potential risks. There is,
however, little knowledge of any adverse consequences
for the resulting large numbers of HIV- and ARV-
exposed but uninfected children, which is essential for
optimal monitoring and management of any potential
hazards.
Birth defects are an initial concern regarding first-tri-
mester exposure to efavirenz. Studies conflict on this
subject [55-57], and the WHO guidelines strongly advise
non-pregnant women on efavirenz to use a secure form
of birth control [3].
A number of studies have also reported conflicting
findings regarding low birth weight and preterm deliv-
eries following exposure to ARVs [58-61]. A 2007 meta-
analysis found a large amount of variation in the differ-
ent studies’ methods and findings [62]. Overall, a greater
risk of preterm delivery was associated with starting tri-
ple-drug therapy before pregnancy or in the first trime-
ster and with the use of protease inhibitors at any point
during pregnancy. An 8192-infant French study asso-
ciated lower birth weights to triple-drug regimens com-
pared with monotherapy, but inferred that the
difference was due to confounding factors [61]. Chief
among these was that pregnant women with advanced
HIV in 1997-2004 were more likely than others to
receive triple therapy. Resolving this nettlesome issue is
essential for choosing PMTCT regimens and planning
infant healthcare in areas of high HIV prevalence.
A further area of disagreement concerns mitochon-
drial toxicity in ARV-exposed, uninfected infants.
Mitochondrial toxicity would lead to such conditions
as lactic acidosis, pancreatitis, cardiomyopathy and
neuropathy. Some cohort studies have observed signs
of mitochondrial impairment in ARV-exposed infants
[63,64]. Researchers have argued, too, that in utero
HIV exposure itself leads to mitochondrial damage
[64,65]. Yet another issue is haematologic toxicities: a
longitudinal study of more than 4000 children aged 0
to 18 months found that haemoglobin levels, white
blood cells and platelets were transiently reduced in
ARV-exposed children [66]. Investigation is also conti-
nuing regarding effects of in utero ARVs on cardiac
function and cardiomyopathy in HIV-exposed but
uninfected infants [67].
Other ARV exposure concerns are an increased risk of
infectious diseases in the newborn and potential for
malignancies later in life [68,69]. There has been no
confirmed elevation in malignancies, but cancers can
take years to develop [70]. Longitudinal studies,
including cohorts that follow up infants and children
into adulthood, are required to answer this question.
As with malignancies, documentation of changes in
growth and development has proved elusive. Here, too,
studies have been carried out until only a few years of
age [71,72]. More extensive and longer follow up is
called for to detect subtle or lingering toxicities. Along
those lines, the Paediatric HIV/AIDS Cohort Study in
the United States has instituted a Surveillance Monitor-
ing of Antiretroviral Toxicity project to prospectively
follow more than 2000 ARV-exposed, uninfected infants
to evaluate late toxicities [73].
The incidence of subtle adverse events is likely to rise
as the length of ARV exposure grows as the revised
WHO guidelines are implemented [3]. Studies of unin-
fected children will have to tease out the separate con-
tributions of exposure to ARVs and maternal HIV and
environmental and economic factors. Understanding
these will be necessary to help identify the best strate-
gies that minimize both the risk of HIV transmission
and any compromise of growth and development. A
more comprehensive pharmacovigilance system, for
example, by expanding the existing network of antiretro-
viral pregnancy registries to include low- and middle-
income paediatric cohorts, should explore models for
longer-term monitoring of uninfected children exposed
in pregnancy and during extended postpartum
prophylaxis.
New treatment options for children with HIV
The paediatric HIV incidence in high-income countries
has shrunk to a very low level due to the success of
PMTCT using suppressive triple-drug regimens. In
resource-limited areas, where PMTCT coverage is sub-
optimal, an estimated 370,000 infants are born annually
with HIV infection [74]. As with adults, WHO’s 2010
paediatric guidelines will greatly broaden the goals for
treating these children [2].
Studies have clearly demonstrated the survival benefits
of providing immediate therapy to HIV-infected infants
[75-77]. A groundbreaking South African study reported
that deferring antiretroviral therapy until CD4 levels
become low or symptoms appear increases infant mor-
tality by more than 400% [78]. WHO, in response,
recommended that all HIV-infected children under one
year of age receive ARVs [76]. It is now raising that
recommendation to the age of two years [9]. Recom-
mendations for children older than two years include
CD4 count and clinical criteria in line with those in the
new adult guidelines.
Provision of immediate treatment to infants requires
that they be identified in timely fashion. Postnatal follow
up is notoriously weak in resource-constrained settings,
and especially so for undiagnosed infants with HIV
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bodies, infants younger than 18 months require sophisti-
cated, expensive virologic testing for a definitive HIV
diagnosis. Only 15% of infants born to HIV-positive
mothers received such testing during the first two
months of life in 54 countries reporting this information
in 2009 [39]. The WHO guidelines include recommen-
dations for symptom-based, presumptive diagnosis of
severe HIV disease in areas where virologic testing is
unavailable.
Strengthening infant services is critical to ensure
prompt diagnosis and retention in HIV care. Integration
of HIV care with other health services, along with task
shifting and sharing, again promises to help ensure
more consistent HIV management. Inclusion of commu-
nity social networks and other household members
(fathers, in particular) will provide substantial support
for these efforts.
An issue particular to children older than age two
years is the effect of ARVs on growth and development.
If the drugs retard development, it would not be advisa-
ble to start ARVs earlier than necessary. The influence
of HIV infection, however, confounds that of ARVs.
Recent reports indicate that children who start treat-
ment with less advanced HIV disease and less growth
deficiency tend to gradually normalize their height and
weight [80-82]. Children who initiate treatment later in
the HIV disease process also gain weight and height, but
at a slower rate. Even so, children remain on a growth
trajectory determined by nutritional and environmental
conditions. Analogous problems exist when studying
other aspects of development, such as neurocognitive
maturation and bone growth.
Starting ARVs also depends on the relationship
between antiretroviral drugs and concurrent conditions.
More research is required in this area, too. A particu-
larly critical area is tuberculosis (TB) treatment in chil-
dren. Mutual liver toxicities and drug-drug interactions
create complicated treatment management problems for
children infected with both HIV and TB. A study in
South African children aged seven months to 3.9 years
showed that it is possible to attenuate the tendency of
lopinavir levels to decline in the presence of the TB
drug, rifampicin, by using a higher dose of concomitant
ritonavir (lopinavir/ritonavir ratio of 1:1 instead of the
usual 4:1) [83]. The drawback is that children then have
appreciable elevations in serum liver enzymes [84].
Paediatric treatment problems would be easier to
resolve if there were as many available antiretroviral
options as there are for adults. Unfortunately, many bar-
riers retard development of paediatric ARV formulations
for resource-restricted settings. Optimal and acceptable
options for infants and children are of growing necessity
because of concern about resistance due to single-dose
nevirapine exposure during PMTCT, and also concern
about emergence of resistance during treatment in chil-
dren [85,86].
There is now low demand for paediatric ARVs in
high-income countries, and so little financial incentive
to bring new formulations to the market. In low- and
middle-income countries, the available liquid paediatric
formulations present a number of practical difficulties:
bulk transport and storage is difficult because liquid for-
mulations tend to have short shelf lives or require
refrigeration. Also, their lack of palatability and large
volume create household obstacles to adherence. The
W H Og u i d e l i n e ss t r e s st h a tf ixed-dose formulations
combining multiple drugs in a single pill would be an
important step to simplifying regimens [2]. Achieving
advances of this order require multisectoral partnerships
involving industry, private donors and international
agencies [87].
Moving forward
The Consensus Statement, “Asking the Right Questions:
Advancing an HIV Research Agenda for Women and
Children”, issued by the IAS and its partners, identifies
the research needed to bring advanced HIV treatment
to women and children in resource-limited countries
[9]. The statement’s overarching recommendations call
for more extensive HIV research on women and chil-
dren, for widely sharing data, and for better dissemina-
tion of results. It makes a special appeal for consistently
designing HIV research to include a provision for gen-
der analysis. This analysis should especially stress signifi-
cant parameters, such as retention in ARV programmes,
sexual and reproductive health, morbidity and mortality,
and loss to follow up (Additional file 1: Box 1).
The Consensus Statement includes several other major
unmet research needs relevant to providing women with
equitable, quality care. Scientific progress requires, first
of all, designing observational cohorts and clinical trials
to permit stratification by sex, race and ethnicity to pro-
vide the missing data needed to determine sex-based
differences in pharmacokinetics and pharmacodynamics,
treatment outcomes and adverse events (Additional file
1: Box 2). Well-designed, prospective impact evaluation
studies could play an instrumental role in identifying
new solutions as programmes are brought up to scale.
For children, the prime unmet need is a comprehen-
sive system for tracking the continuing effects of HIV
drugs. Expanding existing antiretroviral pregnancy regis-
tries to include low- and middle-income paediatric
cohorts is an initial step. These cohorts should explore
models for longer-term monitoring of uninfected chil-
dren exposed in utero and during extended postpartum
prophylaxis. The Consensus Statement further advocates
advancing infant services to ensure prompt diagnosis
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research investment to develop improved paediatric
ARV formulations, as well as advanced modalities for
treating HIV and comorbid conditions in children
(Additional file 1: Box 3).
Women and children alike would benefit from inte-
gration of HIV programmes with broader health services
and a more family-centred approach. This possibility
signals the need to intensify oft-ignored operations
research on care delivery to identify strategies to opti-
mize HIV treatment and PMTCT programmes for var-
ious populations. Special attention needs to be paid to
linking women and children to a continuum of care -
from HIV testing of pregnant women all the way
through provision of PMTCT, early infant testing, and
linkage to paediatric treatment and care as needed. The
need is particularly critical for marginalized adolescents
and adult women, women living in remote areas, single
women, sex workers, women who use drugs, transgen-
der individuals, indigenous women, and women from
ethnic minorities.
Retention strategies are critical here. Investigating the
best means for maintaining contact with infected
mothers and their offspring is vital for successful HIV
management. Local programmes will have to learn how
to adapt to their clients’ cultural backgrounds, providing
services that make them feel respected and safe. Inclu-
sion of community social networks and other household
members, including men, may provide substantial sup-
port for these efforts.
As we summarize here, HIV research has a long way
to go in addressing women and children’ss p e c i f i c
needs. Yet understanding their issues is central to con-
trolling HIV, as well as other diseases. The research
agenda laid out by the statement is designed to result in
new strategic thinking for women and children, and
supports a collaborative effort among key players,
including those from industry.
Additional material
Additional file 1: Boxes. Box 1: Overarching recommendations to
improve research for women and children. Box 2: Recommendations for
clinical and operations research for treatment for women and girls. Box
3: Clinical and operations research recommendations for PMTCT and
paediatric care, treatment and support.
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